Month: May 2024

VANCOUVER, British Columbia, May 13, 2024 (GLOBE NEWSWIRE) — Ascot Resources Ltd. (TSX: AOT; OTCQX: AOTVF) (“Ascot” or the “Company”) is pleased to announce the Company’s unaudited financial results for the three months ended March 31, 2024 (“Q1 2024”), and also to provide a construction update on the Company’s Premier Gold Project (“PGP” or the “project”), located on Nisga’a Nation Treaty Lands in the prolific Golden Triangle of northwestern British Columbia. For details of the unaudited condensed interim consolidated financial statements and Management’s Discussion and Analysis for the three months ended March 31, 2024, please see the Company’s filings on SEDAR+ (www.sedarplus.ca). All amounts herein are reported in $000s of Canadian dollars (“C$”) unless otherwise specified. Q1 2024 AND RECENT HIGHLIGHTSOn May 7, 2024,...

– Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration; Phase 2 on track to begin dosing in the second half of 2024 – – Patient expansion phase well underway in Phase 2 study of luvelta in combination with bevacizumab; enrollment is expected to complete in the first half of 2024 – – The randomized portion of REFRαME-O1, the registration-enabling study of luvelta for patients with platinum-resistant ovarian cancer, is active and enrolling – – As of March 31, 2024, Sutro had cash and investments of $267.6 million and shares of Vaxcyte common stock valued at $45.6 million – – In April, Sutro further bolstered its cash position with $75 million in upfront payments and an equity investment from licensing exclusive...

Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Enrollment continues into the Phase 3 portion of the IMPAHCT trial of AV-101  Poster to be presented with baseline characteristics of the Phase 2b portion of the IMPAHCT trial at the ATS 2024 Conference on May 21  Cash runway into 2026, based on our current operating plan  WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the quarter ended March 31, 2024, and recent business highlights. Recent Highlights Topline Data Expected in...

On track to submit NDA in the second half of 2024 for Tonmya™ for fibromyalgia; pre-NDA meeting with FDA scheduled for second quarter 2024 Commercial planning continues for U.S. launch of Tonmya, a potential new first-line, centrally-acting, non-opioid analgesic for the management of fibromyalgia CHATHAM, N.J., May 13, 2024 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced financial results for the first quarter ended March 31, 2024, and provided an overview of recent operational highlights. “Our near-term priority continues to be the submission of our New Drug Application (NDA) for Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the management...

BOCA RATON, Fla., May 13, 2024 (GLOBE NEWSWIRE) — FlexShopper, Inc. (Nasdaq:FPAY) (“FlexShopper”), a leading national online lease-to-own (“LTO”) retailer and payment solution provider for underserved consumers, today announced its financial results for the quarter ended March 31, 2024. Results for Quarter Ended March 31, 2024, vs. Quarter Ended March 31, 2023:Total fundings decreased 1.1% to $26.0 million from $26.3 millionTotal revenues increased 10.1% to $33.9 million from $30.8 millionGross profit increased 30.9% to $17.8 million from $13.6 millionAdjusted EBITDA1 increased by $1.2 million to $7.6 million from $6.4 millionOperating income increased 19.0% to $5.0 million from $4.2 millionNet loss attributable to common stockholders of $(1.3) million, or $(0.06) per diluted share, compared to net loss attributable...

SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) — Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. “We are excited about the therapeutic potential of our pipeline of next-generation Selected TIL therapies,” said Sammy Farah, M.B.A., Ph.D., Turnstone’s President and Chief Executive Officer. “The next frontier for TIL therapy is to extend its therapeutic activity in additional solid tumor indications beyond melanoma. Our differentiated approach includes a proprietary ‘cell selection’ step which is designed...

VANCOUVER, British Columbia, May 13, 2024 (GLOBE NEWSWIRE) — Glacier Media Inc. (TSX: GVC) (“Glacier” or the “Company”) reported revenue and earnings for the period ended March 31, 2024. SUMMARY RESULTS(thousands of dollars)   Three months ended March 31,  except share and per share amounts     2024       2023           Revenue   $ 34,750     $ 39,218  EBITDA (1)   $ (322 )   $ (2,241 )EBITDA (1) margin     (0.9 %)     (5.7 %)EBITDA (1) per share   $ (0.00 )   $ (0.02 )Capital expenditures   $ 759     $ 1,077  Net loss attributable to common shareholder   $ (4,429 )   $ (5,217 )Net loss attributable to common shareholder per share   $ (0.03 )   $ (0.04 )         Weighted average shares outstanding, net     131,131,598       132,329,984           (1)  EBITDA is considered a non-GAAP measure....

Company hosting in-person R&D day event, focused on atrioventricular interval modulation (“AVIM”) therapy, including the unmet need in hypertension, mechanism of action, clinical results and design of the BACKBEAT study in New York City on June 11, 2024NEW HOPE, Pa., May 13, 2024 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its first quarter 2024 financial results and provided a business update. “Since initiating patient enrollment of the BACKBEAT global pivotal study, our team has been hard at work alongside our colleagues at Medtronic to activate study sites and support patient enrollment in the U.S. and EU,” commented David Hochman,...

Annual Meeting and Shareholder Presentation to be held virtually on May 15, 2024 at 10:00 a.m. HST KAPALUA, Hawaii, May 13, 2024 (GLOBE NEWSWIRE) — Maui Land & Pineapple Company, Inc. (NYSE: MLP) today reported financial results covering the three month period ended March 31, 2024. The company’s annual meeting and shareholder presentation will be held virtually on May 15, 2024 at 10:00 a.m. Hawaii Standard Time, via meeting link posted on mauiland.com/investors. “Maui Land & Pineapple Company’s renewed mission to maximize the productive use of our diverse portfolio of land and commercial properties is starting to yield tangible results,” said CEO Race Randle. “Despite the challenges following the 2023 Maui wildfires, concerted efforts to reposition and increase occupancy at the Kapalua Village and Hali‘imaile Town Centers...